药物基因组学的创新模型，关键结果鉴定和干预。

IF 2.9 3区医学 Q2 GENETICS & HEREDITY

Pharmacogenomics Journal Pub Date : 2025-10-02 DOI:10.1038/s41397-025-00385-y

Ryley Uber, Vanessa A Hayduk, Alison Flango, Theron Ward, Leeann Webster, Eric A Wright

{"title":"药物基因组学的创新模型，关键结果鉴定和干预。","authors":"Ryley Uber, Vanessa A Hayduk, Alison Flango, Theron Ward, Leeann Webster, Eric A Wright","doi":"10.1038/s41397-025-00385-y","DOIUrl":null,"url":null,"abstract":"Pharmacogenomics (PGx) test results are returned variably across healthcare settings, which can lead to challenges particularly when results require immediate intervention to avoid adverse consequences. While several return of result models exist in literature, a standard-of-care has not been established. We propose a model to safely return PGx results in the context of scaled and sustained PGx testing: an institutional protocol to integrate new PGx results into patient care.","PeriodicalId":54624,"journal":{"name":"Pharmacogenomics Journal","volume":"25 5","pages":"25"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An innovative model for pharmacogenomics critical results identification and intervention.\",\"authors\":\"Ryley Uber, Vanessa A Hayduk, Alison Flango, Theron Ward, Leeann Webster, Eric A Wright\",\"doi\":\"10.1038/s41397-025-00385-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pharmacogenomics (PGx) test results are returned variably across healthcare settings, which can lead to challenges particularly when results require immediate intervention to avoid adverse consequences. While several return of result models exist in literature, a standard-of-care has not been established. We propose a model to safely return PGx results in the context of scaled and sustained PGx testing: an institutional protocol to integrate new PGx results into patient care.\",\"PeriodicalId\":54624,\"journal\":{\"name\":\"Pharmacogenomics Journal\",\"volume\":\"25 5\",\"pages\":\"25\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41397-025-00385-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41397-025-00385-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

摘要

药物基因组学（PGx）测试结果在医疗保健设置中返回变量，这可能导致挑战，特别是当结果需要立即干预以避免不良后果时。虽然文献中存在一些结果回归模型，但尚未建立护理标准。我们提出了一个模型，在规模和持续的PGx测试的背景下安全地返回PGx结果：一个机构协议，将新的PGx结果整合到患者护理中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

An innovative model for pharmacogenomics critical results identification and intervention.

Pharmacogenomics (PGx) test results are returned variably across healthcare settings, which can lead to challenges particularly when results require immediate intervention to avoid adverse consequences. While several return of result models exist in literature, a standard-of-care has not been established. We propose a model to safely return PGx results in the context of scaled and sustained PGx testing: an institutional protocol to integrate new PGx results into patient care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacogenomics Journal 医学-药学

CiteScore

7.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Pharmacogenomics Journal is a print and electronic journal, which is dedicated to the rapid publication of original research on pharmacogenomics and its clinical applications. Key areas of coverage include: Personalized medicine Effects of genetic variability on drug toxicity and efficacy Identification and functional characterization of polymorphisms relevant to drug action Pharmacodynamic and pharmacokinetic variations and drug efficacy Integration of new developments in the genome project and proteomics into clinical medicine, pharmacology, and therapeutics Clinical applications of genomic science Identification of novel genomic targets for drug development Potential benefits of pharmacogenomics.